Effectiveness of mRNA COVID-19 Monovalent and Bivalent Vaccine Booster Doses Against Omicron Severe Outcomes Among Adults Aged ≥50 Years in Ontario, Canada: A Canadian Immunization Research Network Study.

Ramandip Grewal,Kevin L Schwartz,Sarah A Buchan,Sarah E Wilson,Mina Tadrous,Nelson Lee,Lena Nguyen,Jeffrey C Kwong,Peter C Austin,Kumanan Wilson,Kevin A Brown,Sharifa Nasreen,Jonathan Gubbay

doi:10.1093/infdis/jiad419

Effectiveness of mRNA COVID-19 Monovalent and Bivalent Vaccine Booster Doses Against Omicron Severe Outcomes Among Adults Aged ≥50 Years in Ontario, Canada: A Canadian Immunization Research Network Study.

Ramandip Grewal, Kevin L Schwartz + Show 11 more

Open Access

https://doi.org/10.1093/infdis/jiad419

Copy DOI

Journal: Journal of Infectious Diseases	Publication Date: Oct 5, 2023
Citations: 5	License type: CC BY-NC-ND 4.0

Affiliation: Public Health Ontario, University of Toronto, Women's College Hospital, Institute for Clinical Evaluative Sciences, Ottawa Hospital Research Institute, University of Ottawa, Children's & Women's Health Centre of British Columbia

#Canadian Immunization Research Network #Waning Of Protection + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

We estimated the effectiveness of booster doses of monovalent and bivalent mRNA COVID-19 vaccines against Omicron-associated severe outcomes among adults aged ≥50 years in Ontario, Canada. Monovalent and bivalent mRNA COVID-19 booster doses provided similar strong initial protection against severe outcomes. Uncertainty remains around waning of protection from these vaccines.

Full Text